GlassScriptPhysician profile
Chandana Attoti
NPI 1679731624
$3,763.10
in general payments reported to CMS, 2019-2025
25 companies · $704 in 2025
The $704 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $132 · 2021: $302 · 2022: $378 · 2023: $689 · 2024: $876 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $950.21 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $536.30 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $410.93 | 2019-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $266.21 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.34 | 2021-2025 | Jardiance |
| Pfizer INC. | $176.31 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $119.39 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $108.63 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $102.13 | 2023 | Injectafer |
| Boston Scientific Corporation | $98.70 | 2019 | |
| Scpharmaceuticals INC. | $82.81 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $71.70 | 2021-2023 | Xarelto |
| Abbott Laboratories | $70.45 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $70.44 | 2024-2025 | Eliquis, Camzyos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $66.70 | 2020-2025 | Onpattro |
| Gilead Sciences, INC. | $66.15 | 2019 | |
| Bridgebio Pharma, INC. | $49.91 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $38.73 | 2019 | |
| Esperion Therapeutics, INC. | $37.20 | 2022 | |
| Arbor Pharmaceuticals, INC. | $28.77 | 2019-2020 | |
| Inspire Medical Systems, INC. | $25.24 | 2023 | Inspire |
| Althera Pharmaceuticals LLC | $24.26 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $23.08 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $17.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandana Attoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.